Full Press Release Details
Oncolytics Biotech Inc. Announces 2017 First Quarter
CALGARY, May 5, 2017 /CNW/ - Oncolytics Biotech
Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced its financial results and operational highlights for
the quarter ended March 31, 2017.
"The last six months - particularly defining our
clinical development plan and data announced at AACR - have been exciting for us," said Dr. Matt Coffey, President and
CEO of Oncolytics Biotech. "The compelling and statistically significant overall survival data from the IND 213 study in metastatic
breast cancer presented at AACR led us to select this indication as our registration pathway. This is part of our broader
clinical development plan, which is focused on exploiting REOLYSIN's mechanism of action incorporating both cancer cell lysis and
immune system priming and activation."
Since January 1, 2017, selected highlights announced by the
| ONCOLYTICS BIOTECH INC. | |||||
| INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | |||||
| (unaudited) | |||||
| As at | March 31, 2017 $ | December 31, 2016 $ | |||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | 10,102,393 | 12,034,282 | |||
| Short-term investments | - | 2,088,800 | |||
| Accounts receivable | 36,484 | 54,406 | |||
| Prepaid expenses | 182,897 | 260,841 | |||
| Total current assets | 10,321,774 | 14,438,329 | |||
| Non-current assets | |||||
| Property and equipment | 301,534 | 319,955 | |||
| Total non-current assets | 301,534 | 319,955 | |||
| Total assets | 10,623,308 | 14,758,284 | |||
| Liabilities And Shareholders' Equity | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,348,766 | 4,068,664 | |||
| Total current liabilities | 3,348,766 | 4,068,664 | |||
| Shareholders' equity | |||||
| Share capital | |||||
| Authorized: unlimited Issued: March 31, 2017 - 121,258,222 December 31, 2016 - 121,258,222 | 262,311,325 | 262,321,825 | |||
| Contributed surplus | 26,776,933 | 26,643,044 | |||
| Accumulated other comprehensive income | 533,312 | 554,060 | |||
| Accumulated deficit | (282,347,028) | (278,829,309) | |||
| Total shareholders' equity | 7,274,542 | 10,689,620 | |||
| Total liabilities and equity | 10,623,308 | 14,758,284 |
| ONCOLYTICS BIOTECH INC. | ||||
| INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS | ||||
| (unaudited) | ||||
| 2017 | 2016 | |||
| For the three month period ending March 31 | $ | $ | ||
| Expenses | ||||
| Research and development | 2,268,071 | 2,726,129 | ||
| Operating | 1,300,300 | 1,360,412 | ||
| Operating loss | (3,568,371) | (4,086,541) | ||
| Interest | 50,715 | 69,621 | ||
| Loss before income taxes | (3,517,656) | (4,016,920) | ||
| Income tax (expense) recovery | (63) | 145 | ||
| Net loss | (3,517,719) | (4,016,775) | ||
| Other comprehensive income items that may be reclassified to net loss | ||||
| Translation adjustment | (20,748) | (170,059) | ||
| Net comprehensive loss | (3,538,467) | (4,186,834) | ||
| Basic and diluted loss per common share | (0.03) | (0.03) | ||
| Weighted average number of shares (basic and diluted) | 121,258,222 | 118,119,985 |
| ONCOLYTICS BIOTECH INC. | ||||||||||
| INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY | ||||||||||
| (unaudited) | ||||||||||
| Share Capital $ | Contributed Surplus $ | Accumulated Other Comprehensive Income $ | Accumulated Deficit $ | Total $ | ||||||
| As at December 31, 2015 | 261,324,692 | 26,277,966 | 760,978 | (263,689,330) | 24,674,306 | |||||
| Net loss and other comprehensive loss | - | - | (170,059) | (4,016,775) | (4,186,834) | |||||
| Issued, pursuant to "At the Market" Agreement | 274,805 | - | - | - | 274,805 | |||||
| Share issue costs | (375,349) | - | - | - | (375,349) | |||||
| Share based compensation | - | 81,640 | - | - | 81,640 | |||||
| As at March 31, 2016 | 261,224,148 | 26,359,606 | 590,919 | (267,706,105) | 20,468,568 | |||||
| Share Capital $ | Contributed Surplus $ | Accumulated Other Comprehensive Income $ | Accumulated Deficit $ | Total $ | ||||||
| As at December 31, 2016 | 262,321,825 | 26,643,044 | 554,060 | (278,829,309) | 10,689,620 | |||||
| Net loss and other comprehensive loss | - | - | (20,748) | (3,517,719) | (3,538,467) | |||||
| Share issue costs | (10,500) | - | - | - | (10,500) | |||||
| Share based compensation | - | 133,889 | - | - | 133,889 | |||||
| As at March 31, 2017 | 262,311,325 | 26,776,933 | 533,312 | (282,347,028) | 7,274,542 |
| ONCOLYTICS BIOTECH INC. | |||||
| INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
| ( unaudited) | |||||
| 2017 | 2016 | ||||
| For the three month period ending March 31 | $ | $ | |||
| Operating Activities | |||||
| Net loss for the period | (3,517,719) | (4,016,775) | |||
| Amortization - property and equipment | 24,036 | 45,942 | |||
| Share based compensation | 133,889 | 81,640 | |||
| Unrealized foreign exchange loss | 52,032 | 141,295 | |||
| Net change in non-cash working capital | (637,646) | 724,655 | |||
| Cash used in operating activities | (3,945,408) | (3,023,243) | |||
| Investing Activities | |||||
| Acquisition of property and equipment | (5,836) | - | |||
| Redemption (purchase) of short-term investments | 2,088,800 | (27,823) | |||
| Cash provided by (used in) investing activities | 2,082,964 | (27,823) | |||
| Financing Activities | |||||
| "At the Market" equity distribution agreement | (10,500) | (100,544) | |||
| Cash used in financing activities | (10,500) | (100,544) | |||
| Decrease in cash | (1,872,944) | (3,151,610) | |||
| Cash and cash equivalents, beginning of period | 12,034,282 | 24,016,275 | |||
| Impact of foreign exchange on cash and cash equivalents | (58,945) | (631,257) | |||
| Cash and cash equivalents, end of period | 10,102,393 | 20,233,408 |
To view the Company's Fiscal 2017 First Quarter Consolidated
Financial Statements, related Notes to the Consolidated Financial Statements, and Management's Discussion and Analysis, please
see the Company's annual filings, which will be available under the Company's profile at www.sedar.com and on Oncolytics' website
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an immuno-oncology viral-agent, as a potential treatment for a variety
of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator
(IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in
breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the
success of its research and development programs in 2017 and beyond, the Company's planned operations, the value of the additional
patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs;
and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the
Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2017/05/c3189.html
For further information: Oncolytics Investor & Media Contact:
Oncolytics Biotech Inc., Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca;
AXON Media Contact: Marian Cutler, 914-701-0100 ext. 5361, mcutler@axon-com.com
CO: Oncolytics Biotech Inc.
CNW 07:00e 05-MAY-17